Arlington, Va. (PRWEB) March 03, 2015
RxAnte, LLC, the leading platform for improving medication use and drug therapy outcomes through predictive analytics and targeted clinical programs, today announced it has successfully undergone the necessary criteria to complete the Service Organization Control [SOC] 2 Type II audit addressing the security and confidentiality principles under the American Institute of Certified Public Accountants (AICPA) guidelines.
The AICPA’s SOC 2 is designed to report on controls that are relevant to the security of the systems used by service organizations to process user entities' data. It can also be used to address the need for assurance on the confidentiality of the information processed by these systems. RxAnte is committed to protecting the information for millions of lives on behalf of clients, providers, and their patients.
"The SOC 2 attestation demonstrates our strong commitment to security and highlights the investment made to keep our client’s data safe,” said Aaron McKethan, president of RxAnte. “We strive to embody the highest level of internal controls and compliance standards over our operations.”
The examination, led by Moody, Famiglietti and Andronico, conducted a thorough review of RxAnte’s policies and practices, focusing on oversight of the organization, vendor management programs, internal corporate governance, and risk management processes.
RxAnte is the leading platform for improving medication use and drug therapy outcomes through predictive analytics and targeted clinical programs. Its innovative analytics platform is transforming how organizations work with healthcare professionals, care management intervention providers, and patients to improve the use of safe and effective prescription medications. Created by subject matter experts in medication adherence, health IT, and advanced analytics, the “RxAnte Platform” is a patent-pending platform that includes predictive and decision analytics, advanced evaluation methods, and an innovative platform for provider engagement. Learn more at http://www.rxante.com or follow us on Twitter.